Regular follow-up appointments, typically scheduled every 4 to 12 weeks during the initial treatment phase, allow for dose adjustments, side effect management, and monitoring of therapeutic outcomes
If it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule
Research indicates that the dynamic interplay between protein degradation pathways and PTMs offers potential therapeutic targets to modulate the onset of ferroptosis[9]
Semaglutide may be prescribed for type 2 diabetes, or to promote weight loss in people with obesity or overweight
Finally, in obese diabetic individuals, the GLP-1R/GIPR/GcgR tri-agonist may be the most appropriate option, having the greatest potential to improve metabolism by weight-dependent and -independent mechanisms